Plasmalogens and platelet‐activating factor roles in chronic inflammatory diseases

• Published in: BioFactors (Oxford) Vol. 48; no. 6; pp. 1203 - 1216
• Main Authors: Tremblay, Marie‐Ève, Almsherqi, Zakaria A., Deng, Yuru
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.11.2022
• Subjects: aging; Cell Membrane - metabolism; Chronic Disease; Humans; inflammation; metabolic disorders; microglia; neurodegenerative disorders; Phospholipid Ethers - metabolism; plasmalogen; plasmalogen replacement therapy; Plasmalogens - chemistry; Plasmalogens - metabolism; Platelet Activating Factor - metabolism; platelet‐activating factor (PAF); metabolic disorders; plasmalogen replacement therapy; inflammation; platelet-activating factor (PAF); plasmalogen; aging; neurodegenerative disorders; microglia
• ISSN: 0951-6433; 1872-8081
• DOI: 10.1002/biof.1916

Fatty acids and phospholipid molecules are essential for determining the structure and function of cell membranes, and they hence participate in many biological processes. Platelet activating factor (PAF) and its precursor plasmalogen, which represent two subclasses of ether phospholipids, have attracted increasing research attention recently due to their association with multiple chronic inflammatory, neurodegenerative, and metabolic disorders. These pathophysiological conditions commonly involve inflammatory processes linked to an excess presence of PAF and/or decreased levels of plasmalogens. However, the molecular mechanisms underlying the roles of plasmalogens in inflammation have remained largely elusive. While anti‐inflammatory responses most likely involve the plasmalogen signal pathway; pro‐inflammatory responses recruit arachidonic acid, a precursor of pro‐inflammatory lipid mediators which is released from membrane phospholipids, notably derived from the hydrolysis of plasmalogens. Plasmalogens per se are vital membrane phospholipids in humans. Changes in their homeostatic levels may alter cell membrane properties, thus affecting key signaling pathways that mediate inflammatory cascades and immune responses. The plasmalogen analogs of PAF are also potentially important, considering that anti‐PAF activity has strong anti‐inflammatory effects. Plasmalogen replacement therapy was further identified as a promising anti‐inflammatory strategy allowing for the relief of pathological hallmarks in patients affected by chronic diseases with an inflammatory component. The aim of this Short Review is to highlight the emerging roles and implications of plasmalogens in chronic inflammatory disorders, along with the promising outcomes of plasmalogen replacement therapy for the treatment of various PAF‐related chronic inflammatory pathologies.